Back to Semaglutide research
semaglutide glp 1 agonist rct 2019-10-02 ClinicalTrials

New Oral Semaglutide Formulation Matches Current Version's Drug Levels

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

Background

Semaglutide is a widely recognized GLP-1 receptor agonist (a class of drugs that mimic a natural hormone to lower blood sugar and promote weight loss) used effectively for managing type 2 diabetes and obesity. While an oral formulation already exists, new formulations are explored to improve manufacturing or patient convenience. This study specifically compared the bioavailability—the proportion of a drug that enters the circulation and is able to have an active effect—of a novel oral semaglutide formulation (Semaglutide C) against the currently marketed oral formulation in healthy individuals.


semaglutide glp 1 agonist glp-1r
Source: clinicaltrials:NCT04109508 · Ingested 2026-04-03 · Digest: gemini-2.5-flash